Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) specifically targeting these mutations have improved treatment outcomes for patients with this subtype of NSCLC. The selecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Zhenfang, Sun, Jinghan, Zhang, Yunkai, Hesilaiti, Nigaerayi, Xia, Qi, Cui, Heqing, Fan, Na, Xu, Xiaofang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953181/
https://www.ncbi.nlm.nih.gov/pubmed/36830579
http://dx.doi.org/10.3390/biom13020210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953181/
https://www.ncbi.nlm.nih.gov/pubmed/36830579
http://dx.doi.org/10.3390/biom13020210

Ejemplares similares